Talazoparib
- Generic Name
- Talazoparib
- Brand Names
- Talzenna
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14F2N6O
- CAS Number
- 1207456-01-6
- Unique Ingredient Identifier
- 9QHX048FRV
- Background
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...
- Indication
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...
- Associated Conditions
- HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Associated Therapies
- -
A Study of Talazoparib in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT03070548
- Locations
- 🇭🇺
PRA Magyarorszag Kft, Fazis I-es Klinikai Farmakologiai Vizsgalohely, Budapest, Hungary
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT03042910
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Porter Ranch, Porter Ranch, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸UCLA Hematology/Oncology - Pasadena, Pasadena, California, United States
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT02997163
- Locations
- 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT02997176
- Locations
- 🇺🇸
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Clarita, Valencia, California, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Open-Label Extension and Safety Study of Talazoparib
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT02921919
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Burbank, Burbank, California, United States
🇺🇸TRIO-US Central Administration, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 106
- Registration Number
- NCT02912572
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Decitabine and Talazoparib in Untreated AML and R/R AML
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 25
- Registration Number
- NCT02878785
- Locations
- 🇺🇸
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02836028
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Conditions
- Interventions
- Drug: SunitinibDrug: Trastuzumab and PertuzumabDrug: Vemurafenib and CobimetinibDrug: PalbociclibDrug: Nivolumab and IpilimumabDrug: AbemaciclibDrug: Atezolizumab and PHESGODrug: Atezolizumab and TalazoparibDrug: Tucatinib plus Trastuzumab Subcutaneous (SC)Drug: FutibatinibDrug: TalazoparibDrug: TemsirolimusDrug: RegorafenibDrug: OlaparibDrug: PembrolizumabDrug: EntrectinibDrug: Larotrectinib
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 3791
- Registration Number
- NCT02693535
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States
🇺🇸Sutter Auburn, Auburn, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.